All lobbying filings

MCDERMOTT+

MCDERMOTT+ filed a Q3 termination report for PATIENTS FOR AFFORDABLE DRUGS NOW on August 28, 2026, reporting $20,000 in lobbying income.

Lobbying for PATIENTS FOR AFFORDABLE DRUGS NOW · non-partisan national patient organization fighting to lower drug prices

All filings by MCDERMOTT+ · Everything PATIENTS FOR AFFORDABLE DRUGS NOW has reported

Filing · LD-2 quarterly report Q3 termination

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Aug 28, 2026

Income

$20,000

What the client paid this registrant for the period.

Client based in

District of Columbia

Representation ended

Aug 31, 2026

The registrant reported terminating its work for this client.

Official filing document

Lobbyists on this filing 4

AMY KELBICK

Previously held: 2015-2017: Senior Policy Advisor, Rep. Jan Schakowsky; 2013-2015: Senior Legislative Assistant, Rep. Bill Foster; 2009-2013: Legislative Assistant, Staff Assistant, Rep. Maurice Hinchey
DEBRA CURTIS

Previously held: 1998-2013: Legislative Director, Chief of Staff, Rep. Pete Stark; jointly Professional Staff on Committee on Ways and Means, Health Subcommittee
RODNEY WHITLOCK

Previously held: 2011-2015: Health Policy Director, Sen. Chuck Grassley; 2005-2010: Health Policy Advisor, Senate Finance Committee; 2003-2005: Legislative Director, Rep. Charlie Norwood; 1997-2002: Legislative Assistant, Rep. Charlie Norwood
JOSH JORGENSEN New on this filing

Previously held: 2017-2020: Senior Legislative Correspondent; Legislative Aide, Sen. Mike Rounds

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 3

Health Issues

Issues related to prescription drug competition and pricing.

Consumer Issues/Safety/Products

Issues related to prescription drug competition and pricing.

Medicare/Medicaid

Issues related to prescription drug competition, pricing and pharmacy benefit management reforms.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.